Evolus (NASDAQ:EOLS) Hits New 1-Year Low - Here's What Happened

Key Points

• Evolus, Inc. (NASDAQ:EOLS) shares reached a new **52-week low** of $8.65, with a recent trading price of $8.71 and a total volume of **311,804 shares** traded.
• Multiple analysts have reaffirmed a **"buy" rating** for Evolus, with target prices ranging from **$21.00 to $27.00**, suggesting a favorable outlook despite current stock performance.
• Insider buying activity has occurred, with **Director Albert G. White III** purchasing **20,000 shares** at approximately $9.45 each, increasing his stake in the company significantly.

Evolus, Inc. (NASDAQ:EOLS - Get Free Report)'s stock price reached a new 52-week low on Friday . The company traded as low as $8.65 and last traded at $8.71, with a volume of 311804 shares. The stock had previously closed at $8.92.

Analysts Set New Price Targets

A number of equities analysts have weighed in on EOLS shares. BTIG Research started coverage on shares of Evolus in a research report on Thursday, April 17th. They set a "buy" rating and a $21.00 price objective for the company. Needham & Company LLC restated a "buy" rating and set a $22.00 price objective on shares of Evolus in a research report on Thursday, May 8th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $27.00 target price on shares of Evolus in a report on Thursday, April 10th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $23.75.

Evolus Trading Down 1.2%

The company has a debt-to-equity ratio of 22.00, a current ratio of 2.34 and a quick ratio of 2.16. The company has a market cap of $580.32 million, a PE ratio of -10.12 and a beta of 1.12. The company's 50 day simple moving average is $9.46 and its two-hundred day simple moving average is $11.27.

Insider Activity at Evolus

In related news, Director Albert G. White III bought 20,000 shares of the stock in a transaction on Monday, June 9th. The stock was bought at an average price of $9.45 per share, with a total value of $189,000.00. Following the completion of the purchase, the director directly owned 50,378 shares in the company, valued at $476,072.10. This represents a 65.84% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Rui Avelar sold 3,385 shares of the stock in a transaction dated Monday, May 12th. The stock was sold at an average price of $9.87, for a total transaction of $33,409.95. Following the sale, the insider directly owned 359,082 shares in the company, valued at $3,544,139.34. This represents a 0.93% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 153,571 shares of company stock worth $1,537,090. 6.10% of the stock is owned by corporate insiders.

Institutional Trading of Evolus

Several hedge funds have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Evolus by 3.6% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,451 shares of the company's stock worth $347,000 after purchasing an additional 1,094 shares in the last quarter. Tradition Wealth Management LLC raised its holdings in Evolus by 18.2% in the fourth quarter. Tradition Wealth Management LLC now owns 13,000 shares of the company's stock valued at $144,000 after acquiring an additional 2,000 shares in the last quarter. MetLife Investment Management LLC raised its holdings in Evolus by 6.3% in the fourth quarter. MetLife Investment Management LLC now owns 34,272 shares of the company's stock valued at $378,000 after acquiring an additional 2,044 shares in the last quarter. AlphaQuest LLC acquired a new stake in Evolus in the first quarter valued at approximately $39,000. Finally, Rhumbline Advisers raised its holdings in Evolus by 4.1% in the first quarter. Rhumbline Advisers now owns 83,436 shares of the company's stock valued at $1,004,000 after acquiring an additional 3,287 shares in the last quarter. Institutional investors and hedge funds own 90.69% of the company's stock.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.